Do GLP-1 drugs reduce alcohol consumption?
Yes. Clinical and observational data show GLP-1 users (Ozempic, Wegovy, Mounjaro, Zepbound) drink 30-50 percent less alcohol on average. The magnitude at industry scale is still debated, but every major spirits CEO has flagged it as a real long-term volume question.
Yes. GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound consistently reduce alcohol consumption among users by roughly 30-50 percent in published studies and operator surveys. The mechanism is dampened reward response in the brain's nucleus accumbens, which suppresses craving for alcohol alongside food. Diageo, Pernod Ricard, and Brown-Forman have all named GLP-1 as a structural headwind on earnings calls. The industry debate is no longer whether the effect is real but how large it is when scaled across the 10-15 percent of adults projected to be on a GLP-1 by 2030. Liquor Bets runs markets on whether named CEOs cite GLP-1 in guidance cuts in specific reporting periods.